EIGER BIOPHARMACEUTICALS INC (EIGR)

US28249U2042 - Common Stock

1.725  -0.17 (-9.21%)

After market: 1.7 -0.03 (-1.45%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
12.14M13.48M
11.04%		15.773M
17.01%		25.722M
63.08%
EBITDA
YoY % growth
-76.66M
-23.69%		-92.45M
-20.60%		-71.503M
22.66%		5.161M
107.22%		N/AN/AN/AN/AN/A
EBIT
YoY % growth
-76.94M
-23.80%		-92.74M
-20.54%		-71.778M
22.60%		-21.971M
69.39%
Operating Margin
-633.77%-687.98%-455.07%-85.42%
EPS
YoY % growth
-2.37
-2.60%		-18.87
-696.20%		N/A-15.91

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24
EPS
Q2Q % growth		-5.51
64.69%
Revenue
Q2Q % growth		5.659M
37.35%
EBITDA
Q2Q % growth		N/AN/AN/AN/A
EBIT
Q2Q % growth		-7.364M
66.90%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2023
Q2Q % growth		 -12.30
-1,883.87%		-9.90-2.40-24.19%
Q2 2023
Q2Q % growth		 -14.10
-2,664.71%		-12.55-1.55-12.39%
Q1 2023
Q2Q % growth		 -15.60
-2,337.50%		-14.47-1.13-7.78%
Q4 2022
Q2Q % growth		 -17.10
-2,571.88%		-16.63-0.47-2.80%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 3.803M
40.85%		6.609M-2.806M-42.46%
Q3 2023
Q2Q % growth		 3.21M
-20.15%		5.014M-1.804M-35.98%
Q2 2023
Q2Q % growth		 4.64M
13.45%		4.66M-20K-0.43%
Q1 2023
Q2Q % growth		 4.12M
54.31%		4.244M-124K-2.92%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% -159.02% 0% -2900%
Revenue0% 0% 0% 0%